International journal of clinical oncologyHumansMaleFemaleAgedMiddle Aged
Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic options.
Shoma Yamamoto, Minoru Kato, Taisuke Matsue, Nao Yukimatsu, Yuji Takeyama, Taiyo Otoshi, Takeshi Yamasaki, Katsuyuki Kuratsukuri, Junji Uchida
Published: 202610.1007/s10147-025-02919-7
Abstract
OBJECTIVE: Combination therapy with enfortumab vedotin (EV) and pembrolizumab has shown superior overall survival (OS) compared to platinum-based chemotherapy in advanced urothelial carcinoma (UC). Given the expanding landscape of first-line treatmen…
Preview only. Read the full abstract at the source